SI1276495T1 - Uporaba rekombinantnega pljucnega surfaktanta za zgodnje zdravljenje akutnih pljucnih bolezni - Google Patents

Uporaba rekombinantnega pljucnega surfaktanta za zgodnje zdravljenje akutnih pljucnih bolezni

Info

Publication number
SI1276495T1
SI1276495T1 SI200130568T SI200130568T SI1276495T1 SI 1276495 T1 SI1276495 T1 SI 1276495T1 SI 200130568 T SI200130568 T SI 200130568T SI 200130568 T SI200130568 T SI 200130568T SI 1276495 T1 SI1276495 T1 SI 1276495T1
Authority
SI
Slovenia
Prior art keywords
pulmonary
early treatment
recombinant
acute
diseases
Prior art date
Application number
SI200130568T
Other languages
English (en)
Inventor
Dietrich Hofner
Andreas Keller
Frank Rathgeb
Peter Schaffer
Wilhelm Wurst
Christoph Karl
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of SI1276495T1 publication Critical patent/SI1276495T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI200130568T 2000-04-12 2001-04-12 Uporaba rekombinantnega pljucnega surfaktanta za zgodnje zdravljenje akutnih pljucnih bolezni SI1276495T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00107858 2000-04-12
PCT/EP2001/004223 WO2001076619A1 (en) 2000-04-12 2001-04-12 Novel use of pulmonary surfactant for the prophylaxis or early treatment of acute pulmonary diseases

Publications (1)

Publication Number Publication Date
SI1276495T1 true SI1276495T1 (sl) 2006-10-31

Family

ID=8168443

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200130568T SI1276495T1 (sl) 2000-04-12 2001-04-12 Uporaba rekombinantnega pljucnega surfaktanta za zgodnje zdravljenje akutnih pljucnih bolezni

Country Status (12)

Country Link
US (1) US20030158087A1 (sl)
EP (1) EP1276495B1 (sl)
JP (1) JP2003530356A (sl)
AT (1) ATE323505T1 (sl)
AU (1) AU2001265876A1 (sl)
CA (1) CA2405811C (sl)
DE (1) DE60118898T2 (sl)
DK (1) DK1276495T3 (sl)
ES (1) ES2262656T3 (sl)
PT (1) PT1276495E (sl)
SI (1) SI1276495T1 (sl)
WO (1) WO2001076619A1 (sl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040254112A1 (en) * 2000-04-12 2004-12-16 Dietrich Hafner Use of pulmonary surfactant for the early treatment of acute pulmonary diseases
WO2003053455A1 (en) 2001-12-12 2003-07-03 Penn State Research Foundation Surfactant prevention of lung complications from cancer chemotherapy
ITMI20021058A1 (it) * 2002-05-17 2003-11-17 Chiesi Farma Spa Miscele di lipidi sintetici ottimizzate per la preparazione di un surfattante ricostituito
US7238664B2 (en) * 2003-06-16 2007-07-03 Altana Pharma Ag Composition comprising a pulmonary surfactant and a PDE5 inhibitor for the treatment of lung diseases
US8236750B2 (en) 2004-08-06 2012-08-07 Nycomed Gmbh Composition comprising a pulmonary surfactant and a TNF-derived peptide
PT2410981T (pt) * 2009-03-26 2017-05-25 Pulmatrix Inc Formulações em pó seco e métodos para tratar doenças pulmonares
EP2407150A1 (de) * 2010-07-16 2012-01-18 Justus-Liebig-Universität Gießen Nano- und Mikropolymerpartikel zur Aufrechterhaltung einer niedrigen Oberflächenspannung in der Lunge und zum Schutz des pulmonalen Surfactants

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013619A (en) * 1988-01-06 2000-01-11 The Scripps Research Institute Pulmonary surfactants and therapeutic uses, including pulmonary lavage
GB9021080D0 (en) * 1990-09-26 1990-11-07 Univ Western Ontario Lipid extract surfactant and method of producing same
DE4418936A1 (de) * 1994-05-31 1996-02-08 Byk Gulden Lomberg Chem Fab Polypeptid
DE4434629C1 (de) * 1994-09-28 1996-06-27 Byk Gulden Lomberg Chem Fab Zusammensetzungen zur Behandlung von IRDS und ARDS
US6129934A (en) * 1995-06-07 2000-10-10 Ony, Inc. Modification of animal lung surfactant for treating respiratory disease due to lung surfactant deficiency or dysfunction
AU7449698A (en) * 1997-05-21 1998-12-11 Medion Research Laboratories Inc. Therapeutic agents for respiratory diseases
DE19827907C2 (de) * 1998-06-23 2003-05-15 Altana Pharma Ag Neue pharmazeutische Zusammensetzungen zur Behandlung von IRDS und ARDS
ATE308976T1 (de) * 1998-11-10 2005-11-15 Altana Pharma Ag Lungensurfactant zubereitungen enthaltendes behandlungset
SI1173194T1 (sl) * 1999-01-19 2004-12-31 Altana Pharma Ag Rekombinantni SP-A za zdravljenje in preprečevanje pulmonalne infekcije in vnetja
US20040254112A1 (en) * 2000-04-12 2004-12-16 Dietrich Hafner Use of pulmonary surfactant for the early treatment of acute pulmonary diseases

Also Published As

Publication number Publication date
DE60118898T2 (de) 2006-11-16
EP1276495A1 (en) 2003-01-22
US20030158087A1 (en) 2003-08-21
ATE323505T1 (de) 2006-05-15
DE60118898D1 (de) 2006-05-24
WO2001076619A1 (en) 2001-10-18
AU2001265876A1 (en) 2001-10-23
EP1276495B1 (en) 2006-04-19
CA2405811C (en) 2011-09-27
JP2003530356A (ja) 2003-10-14
CA2405811A1 (en) 2001-10-18
PT1276495E (pt) 2006-08-31
ES2262656T3 (es) 2006-12-01
DK1276495T3 (da) 2006-08-14

Similar Documents

Publication Publication Date Title
ZA200306806B (en) Preparation for the prophylaxis of restenosis.
NO20034056D0 (no) Proliferative sykdommer
HK1046403A1 (en) Nematicidal trifluorobutenes.
NO20041917L (no) Spesifikke midler som binder humant angiopoietin-2
ATE424413T1 (de) Analoge des glucagon-ähnlichen peptids-1
PL365683A1 (en) Selected fused pyrrolocarbazoles
HK1070008A1 (en) Combination of cytochome p 450 dependent protease inhibitors
AU2001235006A1 (en) Prophylactic and therapeutic monoclonal antibodies
DE60120712D1 (en) Kallikrein gen
MXPA03003741A (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
SI1276495T1 (sl) Uporaba rekombinantnega pljucnega surfaktanta za zgodnje zdravljenje akutnih pljucnih bolezni
AU2002362505A1 (en) Compression sleeve for treatment of the extremities
WO2001051511A3 (de) Rekombinante herstellung von humanen histon 1-subtypen sowie deren verwendung für therapeutische zwecke
ATE401337T1 (de) Antiangiogene polypeptide
SI1173194T1 (sl) Rekombinantni SP-A za zdravljenje in preprečevanje pulmonalne infekcije in vnetja
AU2002251202A1 (en) Intimins for the prevention or treatment of infections: i
WO2002092625A3 (en) Moraxella(branhamella) catarrhalis antigens
AU4453301A (en) Use of spirolaxin for the treatment of diseases associated with abnormal angiogenesis
WO2001039573A3 (de) Verwendung von lungensurfactant zur behandlung von legionärskrankheit
MXPA03009228A (es) Uso de proteina uk 114 o de fragmentos de la misma para tratamiento y prevencion de choque endotoxico.
IT1318676B1 (it) Procedimento e miscela per la preparazione di solfuri metallici.
ITRM20000351A0 (it) Preparato e suo procedimento di preparazione per la prevenzione e/o la cura della caduta di capelli.
IT1318393B1 (it) Materiali proteici per la diagnosi, la profilassi e la terapiadell'infezione da citomegalovirus umano.
WO2002023784A3 (en) Cysteine protease inhibitors
ZA200308844B (en) Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease.